Background:

Teicoplanin A2-5, derived from Actinoplanes teichomyceticus, is a glycopeptide antibiotic which produces a broad spectrum of antibiotic activity against gram-positive bacteria.

Teicoplanin A2-5 is the most non-polar metabolite in the family of teicoplanins. Teicoplanin, previously referred to in the literature as teichomycin, is a mixture of five closely related components of similar polarity, designated T-A2-1, 2, 3, 4 and 5 and of one more polar component, designated T-A3. Additionally, as a glycopeptide antibiotic belonging to the same family as vancomycin, teicoplanin blocks cell wall synthesis in Bacillus subtilis, which is accompanied by an intracellular accumulation of UDP-N-acetylmuramyl-pentapetide [1]. Due to the greater antibacterial activity of teicoplanin than other agents, it has been thoroughly studied as a β-1actamase-resistant agent for the treatment of human infections caused by streptococci and staphylococci, including enterococci [2].

In vitro: Up to now, in vitro study of Teicoplanin A2-5 is still in the development stage.

In vivo: Up to now, in vivo study of Teicoplanin A2-5 is still in the development stage.

参考文献:
[1].  Somma, S., Gastaldo, L., & Corti, A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrobial Agents and Chemotherapy. 1984; 26(6): 917-923.
[2].  Traina, G., & Bonati, M. Pharmacokinetics of teicoplanin in man after intravenous administration. Journal of Pharmacokinetics and Biopharmaceutics. 1984;12(2): 119-128.